Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY   US02043Q1076

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/30/2015 05/01/2015 05/04/2015 05/05/2015 05/06/2015 Date
101.87(c) 106.89(c) 107.16(c) 104.03(c) 105.505 Last
855 586 786 430 684 407 751 252 336 862 Volume
-2.06% +4.93% +0.25% -2.92% +1.42% Change
More quotes
Financials ($)
Sales 2015 52,3 M
EBIT 2015 -254 M
Net income 2015 -236 M
Finance 2015 808 M
Yield 2015 -
Sales 2016 54,8 M
EBIT 2016 -262 M
Net income 2016 -269 M
Finance 2016 639 M
Yield 2016 -
PER 2015 -
PER 2016
EV / Sales 2015 152x
EV / Sales 2016 148x
Capitalization 8 738 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which develops novel therapeutics based on RNA interference.It is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including... 
Sector
Biotechnology & Medical Research
Calendar
05/06 | 04:10pmPresentation
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
05/05 ALNYLAM PHARMACEUTICALS : Submission of Matters to a Vote of Security Holders (f..
04/30 ALNYLAM PHARMACEUTICALS : to Webcast Conference Call Discussing First Quarter 20..
04/30 BIOMED REALTY : Alnylam Pharmaceuticals Inks Lease for Class A Laboratory and Of..
04/29 ALNYLAM PHARMACEUTICALS : to Webcast Presentations at Upcoming May Investor Conf..
04/27 ALNYLAM PHARMACEUTICALS : Updates on 12-Month Clinical Data from Phase 2 Open La..
04/22 ALNYLAM PHARMACEUTICALS : and Collaborators Publish Pre-clinical Study Results i..
04/21 ALNYLAM PHARMACEUTICALS : Reports 12-Month Clinical Data from Phase 2 Open Label..
04/20 BIOMED REALTY : Alnylam Pharmaceuticals Signs Lease for Class A Laboratory and O..
More news
Sector news : Biotechnology & Medical Research - NEC
08:36a PUMA BIOTECHNOLOGY : to Present at Bank of America Merrill Lynch Health Care Con..
05/05DJAbbVie Wraps Up Large Debt Sale for Pharmacyclics Deal
05/05DJAbbVie Wraps Up Large Debt Sale For Pharmacyclics Deal
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
05/01 NEXT WEEK IN BIOTECH : Earnings Deluge - From GSK And Achillion To Intercept And..
04/28 Is Alnylam In 2020 Worth $9 Billion Now?
04/24 SEEKING ALPHA'S BIOTECH WEEKLY : Gilead Isn't Perfect, Biogen-Bass, Spring Fever..
04/24 INSIDERINSIGHTS.COM DAILY ROUND UP 4 : Ge, omn, cocp, agco
04/23 Alnylam Strengthens Its Clinical Case Once Again


Comments 
Advertisement
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF